DiaCarta
DiaCarta Radiation Toxicity Liquid Biopsy Test Deployed in Florida Cancer Treatment Response Project
DiaCarta's RadTox cell-free DNA test will be used throughout Florida as part of a $1 million research project financed by the Florida Cancer Innovation Fund.
DiaCarta, OncoAssure Collaborate on Prostate Cancer LDT Launch
The firms said that DiaCarta's laboratory facilities in California will be used to validate the prostate cancer assay for a commercial launch.
DiaCarta OTC Fecal Occult Blood Test Receives FDA Clearance
The at-home iColon Fecal Occult Blood Test detects blood in stool samples and complements DiaCarta's ColoScape test for the early detection of colorectal cancer.
DiaCarta, Hopkins MedTech Partner to Offer LDT and IVD Validation Services
The companies aim to fill an unmet need by shepherding diagnostic companies through regulatory and clinical lab validation processes.
DiaCarta SPAC Merger Scuttled on Allegations of Wrongdoing
DiaCarta said it received notice that special purpose acquisition company HH&L Acquisition was ending the business combination agreement signed in October 2022.